Skip to content
OpenCapital
Get started

Monte Rosa Therapeutics, Inc. GLUE Continuing operations (in dollars per share)

Continuing operations (in dollars per share) at other companies

Advanced Micro Devices logo
Advanced Micro DevicesAMD
$0.83+88.6%
Airbnb logo
AirbnbABNB
$0.26+8.3%
Monster Beverage logo
Monster BeverageMNST
$0.58+28.9%
Keysight Technologies logo
Keysight TechnologiesKEYS
$1.26+43.0%
VTR
VentasVTR
$0.12+9.1%
Carrier Global logo
Carrier GlobalCARR
$0.28-40.4%

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.76B+361%
Enterprise value$1.64B+381%
P/S41×+38.6×

Profitability

See full
Operating margin-345.2%—
Net margin-302.6%—
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%—
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share)?
Monte Rosa Therapeutics, Inc. (GLUE) reported continuing operations (in dollars per share) of -$0.45 in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share) changed year-over-year?
Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share) decreased by 178.9% year-over-year, from $0.57 to -$0.45.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share)?
Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share) has grown at a -55.2% compound annual growth rate (CAGR), from -$2.29 to -$0.46.